The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival outcomes and functional results of VOLTAGE-A: Preoperative chemoradiotherapy (CRT) and consolidation nivolumab (nivo) in patients (pts) with both microsatellite stable (MSS) and microsatellite instability–high (MSI-H) locally advanced rectal cancer (LARC).
 
Yuichiro Tsukada
No Relationships to Disclose
 
Hideaki Bando
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Ono Pharmaceutical
 
Koji Inamori
No Relationships to Disclose
 
Masashi Wakabayashi
Honoraria - Nihon Medi-Physics
 
Yosuke Togashi
Honoraria - Bristol-Myers Squibb; Chugai Pharma; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Sonire Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); KORTUC (Inst); KOTAI (Inst); Ono Pharmaceutical (Inst)
 
Shohei Koyama
Honoraria - Chugai Pharma; MSD; Ono Pharmaceutical
Research Funding - Ono Pharmaceutical; Otsuka
 
Daisuke Kotani
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; Merck Serono; MSD; Ono Pharmaceutical; Pfizer; Sysmex; Taiho Pharmaceutical; Takeda
Research Funding - CMIC (Inst); CMIC (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); SERVIER (Inst); Syneos Health (Inst)
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Shigenori Homma
No Relationships to Disclose
 
Akinobu Taketomi
No Relationships to Disclose
 
Mamoru Uemura
No Relationships to Disclose
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda
Research Funding - Chugai Pharma
 
Makoto Fukui
No Relationships to Disclose
 
Motohiro Kojima
No Relationships to Disclose
 
Akihiro Sato
Honoraria - AstraZeneca; Dainippon Sumitomo Pharma
Research Funding - Aspyerian Therapeutics (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); MSD (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Pentax Medical Devices; Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiroyoshi Nishikawa
Stock and Other Ownership Interests - Cellian-Biclo; Sustainable Cell Therapeutics
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; MSD K.K; Ono Pharmaceutical
Research Funding - Asahi Kasei; Astellas Pharma; Bayer Yakuhin; Becton Dickinson; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Debiopharm Group; Eisai; Fujifilm; Hitachi; Janssen Research & Development; Kyowa Kirin; MSD K.K.; Oncolys BioPharma; Ono Pharmaceutical; Rakuten Medical; SRL Diagnostics; Sumitomo Dainippon Pharma; Sysmex; Taiho Pharmaceutical; Zenyaku Kogyo
 
Masaaki Ito
No Relationships to Disclose
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Genomedia (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)